updated 3/31/2011 9:16:34 AM ET 2011-03-31T13:16:34

WEST LAFAYETTE, Ind., March 31, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that Ron Ellis, president and CEO of Endocyte, will present at the upcoming Leerink Swann Cancer Roundtable Conference on Thursday, April 7th, 2011, at 11:20 a.m. EDT. Mr. Ellis also will be participating on a panel entitled, "First in Class Agents on the Horizon and Novel Platforms for Cancer," at 9:45 a.m. EDT. The conference is being held at the Roosevelt Hotel in New York City.

A live audio webcast of the Company's presentation can be accessed at http://www.wsw.com/webcast/leerink21/ecyt/ or under "Events & Presentations" in the Investor Relations section of Endocyte's website at www.endocyte.com . The webcast will be archived shortly after the live event and a replay will be available on the Company's website for 90 days following the conference.

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

CONTACT: Vickey Buskirk
         Endocyte Inc.
         (765) 807-0617
         Stephanie Ascher
         Stern Investor Relations, Inc.
         (212) 362-1200

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com